
PODD
Insulet Corp
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
336.020
Open
330.310
VWAP
333.30
Vol
431.49K
Mkt Cap
23.59B
Low
327.8637
Amount
143.81M
EV/EBITDA(TTM)
48.57
Total Shares
70.04M
EV
24.00B
EV/OCF(TTM)
47.39
P/S(TTM)
10.40
Insulet Corporation is a medical device company. It is primarily engaged in the development, manufacture and sale of its continuous insulin delivery systems for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5), the Omnipod DASH Insulin Management System, and the Omnipod Insulin Management System. The Omnipod platform offers continuous insulin delivery that provides various benefits of insulin pump therapy in a way without the need for external tubing required with conventional pumps. The small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod), can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh, or lower back, and delivers insulin into the body through a small flexible tube. It also produces pods for Amgen for use in the Neulasta Onpro kit, a delivery system for Amgen’s Neulasta to help reduce the risk of infection after intense chemotherapy.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
677.30M
+24.53%
1.147
+27.48%
728.28M
+21.89%
1.338
+16.36%
693.13M
+21.82%
1.148
+12.56%
Estimates Revision
The market is revising Upward the revenue expectations for Insulet Corporation (PODD) for FY2025, with the revenue forecasts being adjusted by 4% over the past three months. During the same period, the stock price has changed by 8.92%.
Revenue Estimates for FY2025
Revise Upward

+4%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward

+7.99%
In Past 3 Month
Stock Price
Go Up

+8.92%
In Past 3 Month
18 Analyst Rating

7.42% Upside
Wall Street analysts forecast PODD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PODD is 360.00 USD with a low forecast of 300.00 USD and a high forecast of 415.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
1 Hold
0 Sell
Strong Buy

7.42% Upside
Current: 335.120

Low
300.00
Averages
360.00
High
415.00

7.42% Upside
Current: 335.120

Low
300.00
Averages
360.00
High
415.00
Oppenheimer
NULL -> Outperform
initiated
$324 -> $365
2025-09-08
Reason
Oppenheimer
Price Target
$324 -> $365
2025-09-08
initiated
NULL -> Outperform
Reason
Oppenheimer assumed coverage of Insulet with an Outperform rating and price target of $365, up from $324. The firm updated the company's model post the Q2 report. Insulet has several new near-term catalysts, including the launch of its Omnipod 5 insulin pump and international expansion, the analyst tells investors in a research note.
Barclays
Equal Weight
maintain
$266 -> $300
2025-08-21
Reason
Barclays
Price Target
$266 -> $300
2025-08-21
maintain
Equal Weight
Reason
Barclays raised the firm's price target on Insulet to $300 from $266 and keeps an Equal Weight rating on the shares. The firm updated the company's model to reflect management's commentary and updated 2025 outlook.
Canaccord
Buy
maintain
$331 -> $353
2025-08-08
Reason
Canaccord
Price Target
$331 -> $353
2025-08-08
maintain
Buy
Reason
Canaccord raised the firm's price target on Insulet to $353 from $331 and keeps a Buy rating on the shares. The firm said Insulet beat revenue estimates across the board and confidently raised its guidance for FY25, with strength expected across all markets and populations.
RBC Capital
Outperform
maintain
$330 -> $350
2025-08-08
Reason
RBC Capital
Price Target
$330 -> $350
2025-08-08
maintain
Outperform
Reason
RBC Capital raised the firm's price target on Insulet to $350 from $330 and keeps an Outperform rating on the shares. The firm cites the company's Q2 earnings beat and revenue beat along with Q3 guidance that was well above consensus with its best-in-class product offering, market access, and execution, the analyst tells investors in a research note. Insulet is attractively positioned ahead as it continues to gain market share and furthers growth in a highly underpenetrated market as its catalysts continue to play out, the firm added.
Baird
Outperform
maintain
$350 -> $360
2025-08-08
Reason
Baird
Price Target
$350 -> $360
2025-08-08
maintain
Outperform
Reason
Baird raised the firm's price target on Insulet to $360 from $350 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results which reaccelerating growth and a growing competitive advantage.
Jefferies
Buy
maintain
$360 -> $375
2025-08-07
Reason
Jefferies
Price Target
$360 -> $375
2025-08-07
maintain
Buy
Reason
Jefferies raised the firm's price target on Insulet to $375 from $360 and keeps a Buy rating on the shares. The company's Q2 report came in well ahead of estimates, which led to a guidance raise across the board, the analyst tells investors in a research note. The firm upped estimates on the "outstanding" quarter.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Insulet Corp (PODD.O) is 67.01, compared to its 5-year average forward P/E of 184.80. For a more detailed relative valuation and DCF analysis to assess Insulet Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Undervalued
5Y Average PE
184.80
Current PE
67.01
Overvalued PE
302.25
Undervalued PE
67.34
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
66.55
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
95.84
Undervalued EV/EBITDA
37.26
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
11.30
Current PS
0.00
Overvalued PS
15.27
Undervalued PS
7.34
Financials
Annual
Quarterly
FY2025Q2
YoY :
+32.88%
649.10M
Total Revenue
FY2025Q2
YoY :
+121.79%
121.10M
Operating Profit
FY2025Q2
YoY :
-88.07%
22.50M
Net Income after Tax
FY2025Q2
YoY :
-87.64%
0.32
EPS - Diluted
FY2025Q2
YoY :
+179.81%
173.20M
Free Cash Flow
FY2025Q2
YoY :
+2.85%
69.67
Gross Profit Margin - %
FY2025Q2
YoY :
+80.26%
16.62
FCF Margin - %
FY2025Q2
YoY :
-91.01%
3.47
Net Margin - %
FY2025Q2
YoY :
-52.35%
10.04
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
946.5K
USD
3
3-6
Months
2.9M
USD
4
6-9
Months
4.0M
USD
2
0-12
Months
1.6M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
36.7K
Volume
1
3-6
Months
195.5K
Volume
3
6-9
Months
267.0K
Volume
4
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
4
135.7K
Volume
Months
6-9
6
483.6K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
946.5K
USD
3
3-6
Months
2.9M
USD
4
6-9
Months
4.0M
USD
2
0-12
Months
1.6M
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
PODD News & Events
Events Timeline
2025-09-16 (ET)
2025-09-16
07:10:48
Insulet anticipates Q3 revenue growth surpassing 22%-25% expectations.

2025-09-16
07:08:35
Insulet's CFO Ana Maria Chadwick to Depart, Flavia Pease to Take Over

2025-08-25 (ET)
2025-08-25
17:03:02
Insulet elevates Eric Benjamin to Chief Operating Officer and appoints Manoj Raghunandanan as Chief Growth Officer.

Sign Up For More Events
Sign Up For More Events
News
8.0
09-22NASDAQ.COMOptions Trading for Insulet (PODD) in the First Week of November 21st
4.5
09-22MarketWatch15 Stocks Outperforming the S&P 500 This Year While Becoming More Affordable
4.0
09-18NASDAQ.COMFELG's Core Assets Suggest a 10% Upside Potential
Sign Up For More News
People Also Watch

INVH
Invitation Homes Inc
29.690
USD
+0.17%

BLDR
Builders FirstSource Inc
121.810
USD
-1.88%

STLD
Steel Dynamics Inc
139.070
USD
-0.14%

ONON
On Holding AG
45.590
USD
+0.80%

PFG
Principal Financial Group Inc
82.210
USD
+0.61%

MDB
MongoDB Inc
323.590
USD
+0.05%

ULTA
Ulta Beauty Inc
518.160
USD
-0.63%

MT
ArcelorMittal SA
35.810
USD
+1.39%

L
Loews Corp
97.240
USD
+0.57%

LUV
Southwest Airlines Co
32.300
USD
-0.68%
FAQ

What is Insulet Corp (PODD) stock price today?
The current price of PODD is 335.12 USD — it has increased 1.29 % in the last trading day.

What is Insulet Corp (PODD)'s business?

What is the price predicton of PODD Stock?

What is Insulet Corp (PODD)'s revenue for the last quarter?

What is Insulet Corp (PODD)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Insulet Corp (PODD)'s fundamentals?

How many employees does Insulet Corp (PODD). have?
